Literature DB >> 1306077

Small airway disease in rheumatoid arthritis.

J H Lee1, G Y Suh, K Y Lee, C G Yoo, Y W Kim, S K Han, Y S Shim, K Y Kim, Y C Han, S D Lee.   

Abstract

Variety of pulmonary lesions are thought to be associated with rheumatoid arthritis (RA). These lesions traditionally have included pleurisy with or without effusion, Caplan's syndrome, pulmonary rheumatoid nodules, diffuse interstitial fibrosis, and pulmonary arteritis and hypertension. But little attention has been paid to the airways in RA. Recently, several reports have suggested an association between airflow limitation and RA, but its incidence is not known. Also whether there exists a parameter of disease activity of RA, suggesting the presence of small airway disease (SAD) is not clear. To answer these questions, the serologic parameters which reflect the disease activity of RA and pulmonary function tests which reflect small airway dysfunction were performed on 36 lifetime nonsmokers with RA who had normal chest x-ray findings. The prevalence of SAD and the relationships between the disease activity parameters of RA and pulmonary function were observed. The results were as follows. The percentages of patients with abnormal values for diffusing capacity, frequency dependence of compliance (C1.0/C0.0), forced expiratory flow 25-75%, Vmax50% and Vmax 75% were 45.5%, 62.5%, 40%, 22.8% and 11.4%, respectively. There was statistically significant negative correlation between C1.0/C0.0 and ESR. But consistent correlation between other pulmonary function tests and clinical and serologic parameters of RA, and differences in pulmonary function between patients who were serologically positive and negative for CRP and FANA, were not found. In conclusion, SAD, without the influence of smoking, is frequently associated with RA, but the presence of SAD cannot be predicted from any clinical and serologic parameters of RA currently in use.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1306077      PMCID: PMC4532112          DOI: 10.3904/kjim.1992.7.2.87

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  35 in total

1.  Nodular rheumatoid disease of the lung with cavitation.

Authors:  C D NOONAN; F B TAYLOR; E P ENGLEMAN
Journal:  Arthritis Rheum       Date:  1963-06

2.  Pleural fluid glucose with special reference to its concentration in rheumatoid pleurisy with effusion.

Authors:  D T CARR; M H POWER
Journal:  Dis Chest       Date:  1960-03

3.  Studies of respiratory physiology in children. I. Mechanics of respiration and lung volumes in 85 normal children 5 to 17 years of age.

Authors:  P J HELLIESEN; C D COOK; L FRIEDLANDER; S AGATHON
Journal:  Pediatrics       Date:  1958-07       Impact factor: 7.124

Review 4.  Pulmonary involvement in the collagen vascular diseases.

Authors:  G W Hunninghake; A S Fauci
Journal:  Am Rev Respir Dis       Date:  1979-03

5.  Normal standards for ventilatory function using an automated wedge spirometer.

Authors:  R M Cherniack; M B Raber
Journal:  Am Rev Respir Dis       Date:  1972-07

6.  Small airways function in nonsmokers with rheumatoid arthritis.

Authors:  C S Sassoon; S W McAlpine; D P Tashkin; A Baydur; F P Quismorio; E S Mongan
Journal:  Arthritis Rheum       Date:  1984-11

7.  Bronchiolitis and rheumatoid arthritis.

Authors:  C A Herzog; R R Miller; J R Hoidal
Journal:  Am Rev Respir Dis       Date:  1981-11

8.  Obliterative bronchiolitis in two rheumatoid arthritis patients treated with penicillamine.

Authors:  K C Murphy; C J Atkins; R C Offer; J C Hogg; H B Stein
Journal:  Arthritis Rheum       Date:  1981-03

9.  Frequency dependence of dynamic compliance in patients with rheumatoid arthritis.

Authors:  E A Hills; S Davies; M Geary
Journal:  Thorax       Date:  1979-12       Impact factor: 9.139

10.  Lung function abnormalities in different connective tissue diseases.

Authors:  C Vitali; G Viegi; S Tassoni; A Tavoni; P Paoletti; E Bibolotti; C Ferri; S Bombardieri
Journal:  Clin Rheumatol       Date:  1986-06       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.